REGN Capital expenditure
Capital expenditure at Regeneron Pharmaceuticals rose to $898M in fiscal 2025, the highest in the 5 years reported, from $756M in 2024.
Payments to acquire property, plant and equipment (or the industry equivalent tag), shown as a positive outflow.
SOURCE: us-gaap:PaymentsToAcquireProductiveAssets · EDGAR CompanyFacts · CIK 872589 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Capital expenditure | Change |
|---|---|---|
| FY2025 | $898M | +$142M |
| FY2024 | $756M | +$37M |
| FY2023 | $719M | +$128M |
| FY2022 | $590M | +$38M |
| FY2021 | $552M | — |
More SAME DATA, OTHER VIEWS
Capital expenditure across coverage → · REGN company view →
Revenue · Net income · Operating cash flow · Free cash flow · Cash & equivalents · Total assets · Shareholders' equity · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.